Research analysts covering Virax Biolabs Group.
Recent press releases and 8-K filings for VRAX.
Virax Biolabs Group Ltd to Hold AGM, Propose Reverse Stock Split and Equity Plan
VRAX
Delisting/Listing Issues
Executive Compensation
Board Change
- Virax Biolabs Group Ltd will hold its Annual General Meeting of Shareholders on March 11, 2026, with a record date of January 12, 2026.
- Shareholders will vote on a proposed Share Consolidation (reverse stock split) at a ratio between 10-for-1 and 15-for-1, to be effective on or prior to July 11, 2026. This measure is primarily intended to help the company regain compliance with Nasdaq's $1.00 minimum bid price rule, for which it received an extension until July 11, 2026.
- The company also proposes to approve and adopt the 2026 Equity Incentive Plan, which reserves 2,000,000 shares for awards, with a maximum aggregate market value of $540,000 based on the January 22, 2026 closing price of $0.27 per share.
- Other proposals include the re-appointment of five directors (James Foster, Nigel McCracken, Evan Norton, Iain Miller, and Nelson Haight) and the ratification of Reliant CPAs PC as auditor for the fiscal year ending March 31, 2026.
7 days ago
Virax Biolabs Group Limited Closes $5 Million Private Placement
VRAX
Convertible Preferred Issuance
New Projects/Investments
- Virax Biolabs Group Limited announced the closing of a private placement on December 4, 2025, generating $5 million in gross proceeds.
- The placement involved the sale of 12,500,000 ordinary shares (or equivalents) and preferred investment options to purchase up to 12,500,000 ordinary shares at a purchase price of $0.40 per ordinary share and associated preferred investment option.
- The net proceeds are intended for working capital and general corporate purposes, which is expected to extend the company's cash runway into the first half of 2028.
- Additionally, the exercise price of Series A and B Preferred Investment Options issued on March 10, 2023, was reduced from $2.934 to $0.40 per share, and their term was extended.
Dec 4, 2025, 9:07 PM
Virax Biolabs Group Ltd. Reports Q2 2026 Financial Results with Continued Losses and Going Concern Warning
VRAX
Earnings
Profit Warning
Demand Weakening
- Virax Biolabs Group Ltd. reported a net loss of $2,343,273 for the six months ended September 30, 2025, an improvement from the $2,756,564 net loss for the same period in 2024.
- Revenues significantly decreased to $1,608 for the six months ended September 30, 2025, down from $4,953 in the prior year, primarily due to an increasing focus on the ViraxImmune platform.
- The company's cash balance stood at $3,345,464 as of September 30, 2025, with current liabilities of $365,473.
- Management has raised substantial doubt about the company's ability to continue as a going concern due to recurring losses, an accumulated deficit of $26,928,015, and negative cash flows from operating activities of $2,760,288 for the six months ended September 30, 2025.
Dec 2, 2025, 9:42 PM
Virax Biolabs Initiates Clinical Studies for ViraxImmune™ and Prepares for FDA Pre-Submission Meeting
VRAX
New Projects/Investments
- Virax Biolabs Group Limited has signed a Research Services Agreement (RSA) with Emory University's Center for the Advancement of Diagnostics for a Just Society (ADJUST Center) to conduct clinical studies of ViraxImmune™.
- These studies will focus on immune profiling in individuals with post-viral syndromes, specifically post-acute sequelae of SARS-CoV-2 (PASC), commonly known as long COVID.
- The collaboration aims to generate clinical data to support Virax's planned regulatory submissions and potential future commercial rollout of ViraxImmune™.
- Virax is preparing for a pre-submission meeting with the U.S. Food and Drug Administration (FDA) in early September 2025 to discuss the proposed intended use and regulatory pathway for ViraxImmune™ in PASC.
Aug 26, 2025, 11:30 AM
Vaxxas Secures $90M Funding and Announces Leadership Change
VRAX
Debt Issuance
New Projects/Investments
CEO Change
- Vaxxas has secured nearly $90 million in funding, including $49.22 million in Series D equity and $40 million in debt facilities, to accelerate the commercialization of its high-density microarray patch (HD-MAP) for needle-free vaccine delivery.
- The capital will be used to scale up production, install semi-automated manufacturing lines, and advance late-stage clinical trials, providing a financial runway into the second half of 2027.
- The company is undergoing leadership changes, with CEO David Hoey stepping down after 14 years and a global search for a new CEO underway.
- Vaxxas' HD-MAP technology has been administered to more than 750 participants across multiple clinical trials, demonstrating strong safety, tolerability, and robust immune responses.
Aug 25, 2025, 7:53 AM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more